FDA Approves Phase 3 Clinical Trials


According to the New York Times, the FDA (Food and Drug Administration) has received some promising results from its preliminary trials and have given the green light to begin a large scale Phase 3 clinical trial for using Ecstasy to treat PTSD. It would be final stage before approving the drug’s legal use.

Regarding the latest trials, researchers are reportedly “optimistic” and have pushed for the FDA to speed up the approval process. “I’m cautious but hopeful,” Dr. Charles R. Marmar, a leading PTSD researcher and head of psychiatry at New York University’s Langone School of Medicine, said. “If they can keep getting good results, it will be of great use. PTSD can be very hard to treat. Our best therapies right now don’t help 30 to 40 percent of people. So we need more options.”

At press time, it’s unclear how long the FDA’s phase 3 trial would take. If approved, ecstasy could be hitting pharmacies by 2021.

You must be logged in to post a comment Login